课题基金 / 基金详情

DEVELOPMENT OF ANTICO RECEPTOR MABS FOR HIV THERAPY

DEVELOPMENT OF ANTICO RECEPTOR MABS FOR HIV THERAPY
用于 HIV 治疗的 Antico 受体 MABS 的开发
批准号:
2793411
负责人:
PAUL J MADDON
金额:
$52.06万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-08-14 至 2002-06-30

项目摘要

项目成果

PAUL J MADDON的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自私募S摘要)。艾滋病研究的一个主要目标是 针对癌症不同阶段的新型抗病毒药物的开发 病毒复制循环。最近,HIV-1与宿主细胞膜的融合已经 已被证明需要某些人类“共受体”分子,这些分子属于 七种跨膜趋化因子受体家族(7-TM),G 蛋白质偶联受体。这些分子提供了极好的靶点 大多数目前获得许可的药品。这个项目的总体目标是 项目是确定抗联合受体单抗(MAbs), 单独使用或与其他抗病毒药物联合使用,可以有效 体外抑制HIV-1复制和体内抗感染作用 现有最好的系统。 在第一阶段的项目中,产生了针对CCR5共受体的单抗 有效地抑制HIV-1进入,而不影响正常的CCR5活性。在 第二阶段项目,将产生HIV-1抑制剂单抗以增加 已知的趋化因子受体分子支持广泛的 病毒分离株。将对单抗的生物学特性进行广泛的评估 以及它们的广度、效力和抗病毒活性的机制。潜力 HIV-1通过改变其共受体的使用模式而产生耐药性 将在一系列广泛的体外研究中进行探索。特定的 抗共受体单抗和其他抗病毒药物的组合将是 检查在预防艾滋病毒-1感染方面可能的协同活动,以及 耐药突变株的研究进展。单抗及其组合可提供 在体外对HIV-1最广泛、最有效和最持久的抑制将是 HU-PBL-SCID和SIV-猕猴HIV-1模型的体内评价 感染。在这里,将测试特定的养生法的保护能力 动物对来自不同HIV-1分离株的病毒的感染。如果 这个项目的成功将指导我们选择人性化的单抗和 作为治疗和治疗的新药物进入临床开发 预防HIV-1感染。 建议的商业应用:不可用
英文摘要
DESCRIPTION: (Adapted from P.I.'s abstract). A major goal of HIV research is the development of new antiviral agents that target distinct stages of the viral replicative cycle. Recently, fusion of HIV-1 with host cell membranes has been shown to require certain human "co-receptor" molecules that belong to the chemokine receptor family of seven transmembrane-spanning (7-TM), G protein-coupled receptors. These molecules provide excellent targets for the majority of currently licensed pharmaceuticals. The overall goal of this project is to determine whether anti-co-receptor monoclonal antibodies (mAbs), used alone or in combination with other antiviral agents, can effectively inhibit HIV-1 replication in vitro and protect against infection in vivo using the best systems available. In the Phase I project, mAbs to the CCR5 co-receptor were generated that potently inhibit HIV-1 entry without affecting normal CCR5 activity. In the Phase II project, HIV-1 inhibitor mAbs will be generated to additional chemokine receptor molecules known to support the entry of a wide range of viral isolates. The mAbs will be extensively evaluated for biologic properties and their breadth, potency and mechanism of antiviral activity. The potential for HIV-1 to develop resistance by altering its patterns of co-receptor usage will be explored in an extensive series of in vitro studies. Specific combinations of anti-co-receptor mAbs and other antiviral agents will be examined for possible synergistic activity in preventing HIV-1 infection and the development of drug resistant mutants. MAbs and combinations that provide the most broad, potent, and sustained inhibition of HIV-1 in vitro will evaluated in vivo in the hu-PBL-SCID and SHIV-macaque models of HIV-1 infection. Here specific regimens will be tested for the ability to protect animals against infection by viruses derived from diverse HIV-1 isolates. If successful, this project would guide our selection of mAbs to be humanized and advanced into clinical development as novel agents for the treatment and prophylaxis of HIV-1 infection. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CCR5 inhibitors that block HIV but not chemokines
  • 批准号:
    6746752
  • 项目类别:
  • 资助金额:
    $30.36万
  • 财政年份:
    2004
  • 负责人:
    PAUL J MADDON
  • 依托单位:
Development of Small-Molecule HIV Entry Inhibitors
  • 批准号:
    6698946
  • 项目类别:
  • 资助金额:
    $89.94万
  • 财政年份:
    2001
  • 负责人:
    PAUL J MADDON
  • 依托单位:
HIV Vaccine Design and Development Team
  • 批准号:
    6374728
  • 项目类别:
  • 资助金额:
    $209.05万
  • 财政年份:
    2000
  • 负责人:
    PAUL J MADDON
  • 依托单位:
HIV Vaccine Design and Development Team
  • 批准号:
    6348770
  • 项目类别:
  • 资助金额:
    $197.43万
  • 财政年份:
    2000
  • 负责人:
    PAUL J MADDON
  • 依托单位:
海外基金